Live feed06:40:00·700dPRReleasevia QuantisnowCellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 MonthsByQuantisnow·Wall Street's wire, on your screen.CLRB· Cellectar Biosciences Inc.Health Care
